- Conditions
- Lymphoma
- Interventions
- Not listed
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 260
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alpha 1-Antitrypsin, COPD, Antibody Deficiency
- Interventions
- 20-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pneumococcal Infections
- Interventions
- PCV21, 20vPCV
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 7 Months to 17 Years
- Enrollment
- 1,268 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Paramount, California • Doral, Florida • Hialeah, Florida + 13 more
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Interventions
- AFX3772, Prevnar 13, Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 42 Days to 90 Days
- Enrollment
- 388 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 42
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
- Conditions
- Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
- Interventions
- Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 4,538 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
- Conditions
- Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
- Interventions
- Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Vaccine, Pneumococcal Disease
- Interventions
- Pneumococcal Vaccine
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Rubella, Measles, Mumps
- Interventions
- Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 5,016 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 62
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- alefacept, polyvalent pneumococcal vaccine
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Diego, California • New York, New York + 1 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
- Biological
- Lead sponsor
- Seema Bhat
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pneumococcal Infections
- Interventions
- 13 valent Pneumococcal Conjugate Vaccine, 23vPS
- Biological
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 70 Years and older
- Enrollment
- 938 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 51
- States / cities
- Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more
- Conditions
- Healthy
- Interventions
- V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Anaheim, California • Hallandale, Florida • Hollywood, Florida + 6 more
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon
- Drug · Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Interventions
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 27
- States / cities
- Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Pneumovax (PPSV23), Prevnar (PCV7)
- Biological
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, PCV20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
- Conditions
- Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
- Interventions
- Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 1,167 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 23
- States / cities
- Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more
- Conditions
- Pneumococcal Pneumonia
- Interventions
- Pharmacist Vaccine Education
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 19 Years to 64 Years
- Enrollment
- 431 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Midlothian, Virginia • Richmond, Virginia
- Conditions
- Meningococcal Disease, Meningococcal Meningitis
- Interventions
- MenACWY-CRM, Routine Vaccines
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 55 Days to 89 Days
- Enrollment
- 751 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Orlando, Florida • West Palm Beach, Florida • Houston, Texas
- Conditions
- Pneumococcal Infections
- Interventions
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
- Conditions
- Primary Immune Deficiency
- Interventions
- Pneumovax, Rabavert, Prevnar, Tetanus diphtheria toxoid
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 802 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 32
- States / cities
- Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more